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COVID-19 and Cannabis Smoking and Vaping:  
Four Things You Should Know 
With the growing attention being given to the medical effects of cannabis, there is good deal of 
inaccurate information circulating on the Internet and social media about the potential positive 
effects of tetrahydrocannabinol (THC) and cannabidiol (CBD), the two major compounds in cannabis, 
on COVID-19. However, there is no scientific evidence that demonstrates the benefits of either THC 
or CBD in preventing or treating COVID-19. On the contrary, the evidence shows that inhaling 
cannabis smoke, as with smoke from other sources such as tobacco, can have negative effects on 
the respiratory system. A compromised respiratory system might, in turn, increase susceptibility to 
COVID-19 and worsen the respiratory symptoms of the disease among those infected. For instance, a 
recent study evaluating the risk factors leading to COVID-19 
complications in 78 cases of COVID-19-induced pneumonia 
showed that people who smoke were 14 times more likely to 
develop COVID-19 complications such as pneumonia 
compared to people who do not smoke (Liu et al., 2020). 
Further studies are needed to determine the extent to which 
cannabis smoking (or vaping) can also represent a risk factor 
for COVID-19-related respiratory complications.  
Here are four important things you should know about 
COVID-19 and cannabis smoking and cannabis vaping: 
1. Cannabis smoke contains many chemicals and fine 
particles that are known to be toxic and carcinogenic, and 
to cause genetic mutations (Moir et al., 2008; Manolis, 
Manolis, & Manolis, 2019). These chemicals are further 
known to cause cardiovascular and respiratory diseases 
and cardiovascular morbidity and mortality (Brook et al., 
2010; Pope et al., 2009; Manolis et al., 2019). When 
smoking cannabis, using either a joint, a bong or a pipe, 
individuals tend to inhale more deeply and to keep the 
smoke in their lungs for longer. These behaviours are intended to expose the respiratory system 
to greater quantities of the psychoactive ingredients in cannabis, but also result in greater 
exposure to toxins and chemicals that can irritate respiratory tissue (Manolis et al., 2019). 
2. Cannabis smoking can have negative impacts on lung health. Cannabis smoking is related to a 
greater incidence of chronic cough and phlegm production (National Academies of Sciences, 
Engineering, and Medicine [NASEM], 2017). Other respiratory symptoms, including wheezing, 
sore throat, chest tightness and hoarse voice, have been extensively reported with regular and 
heavy use of cannabis (Hancox, Shin, Gray, Poulton, & Sears, 2015; Moore, Augustson, Moser, & 
Budney, 2005; Taylor, Poulton, Moffit, Ramankutty, & Sears, 2000; Tetrault, et al., 2007). Long-
Coronavirus disease 2019 (COVID-19) 
is a novel infectious respiratory illness 
first identified in humans in December 
2019 in Wuhan, Hubei, China. It is 
caused by the severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) 
infecting the human respiratory tract. 
SARS-CoV-2 originates from mammals 
other than humans. SARS-CoV-2 causes 
mild to moderate respiratory illness in 
the majority of people. However, there 
is an increased risk of more severe 
symptoms and deaths in vulnerable 
people, such as older adults (aged 65 
and older), people with compromised 
immune systems and people who 
have underlying health issues, such 
as diabetes, cancer, cardiovascular 
disease and respiratory conditions 
(Health Canada, 2020; National 
Institute on Drug Abuse, 2020). 
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term cannabis smoking can worsen respiratory symptoms and lead to more frequent episodes of 
chronic bronchitis (NASEM, 2017). There is emerging evidence that quitting cannabis smoking 
can reverse some of the negative respiratory symptoms associated with its use (NASEM, 2017). 
3. THC from cannabis smoke or in other forms can inhibit the ability of the immune system to 
protect the body from foreign pathogens, thus increasing susceptibility to infections. For example, 
growing evidence from preclinical studies in rodents and monkeys has shown that THC is able to 
suppress the ability of immune system cells and “immune messengers” to modulate an adequate 
immune response (Eisenstein & Meissler (2015) against foreign pathogens such as viruses. In 
humans, some studies have shown that THC can inhibit the functioning of several types of immune 
cells in the lungs (Shay et al., 2003; Tashkin & Roth, 2006), an effect that has been suggested 
to alter the immune system defences of lungs and increases susceptibility to infections. There 
have not been many studies examining the effects of THC and other cannabinoids on the immune 
system in humans (NASEM, 2017) and more studies are needed to confirm the effects of THC on 
immune competencies in both healthy and compromised individuals (NASEM, 2017). However, 
the large body of preclinical evidence supports the hypothesis that THC has a potential affect on 
immune functioning. 
4. Vaping of unregulated cannabis extracts can lead to severe lung and pulmonary illnesses. 
Recently, cannabis vaping products that were mostly purchased on the illegal market have been 
associated with severe pulmonary illness, which in some cases resulted in death (Canadian 
Centre on Substance Use and Addiction, 2019; Centers for Disease Control and Prevention, 
2020; Health Canada, 2019). While it is unknown which substance or substances in these 
products led to these outcomes, the primary agent appears to be vitamin E, which is used as a 
thickener in cannabinoid-infused oils. A recent study has shown that heating vitamin E acetate 
can produce carcinogenic alkenes, benzene and toxic ketene gas (Wu & O’Shea, 2020), 
chemicals that potentially played a role in the pulmonary illnesses associated with vaping 
unregulated cannabis extracts containing high levels of vitamin E acetate. 
Eight Ways to Reduce Your Health Risks 
1. Do not share joints, vaping devices and bongs. 
2. Wash your hands before putting any type of cannabis product in your mouth.  
3. If possible, try to limit your cannabis use to once a week. 
4. Avoid taking deep inhalations and try not to hold your breathe. 
5. Purchase your cannabis products from licensed and regulated retailers. 
6. Use products that contain no more than 100 mg/g (10%) of THC content. 
7. Remember that cannabis can interact with your medication. Speak to your heathcare provider 
before using cannabis. 
8. If you are using cannabis for medical purpose, consult your healthcare provider with any 
questions you may have about medical cannabis use during the COVID-19 pandemic. 
For more information, visit https://www.ccsa.ca/cannabis  
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Conclusions  
There is emerging evidence suggesting that cannabis smoking can have negative consequences on 
an individual’s respiratory system and immune competences. There is no evidence that smoking or 
vaping cannabis can prevent, alleviate or treat COVID-19 symptoms. Cannabis smoking or vaping 
could worsen the respiratory symptoms of COVID-19. The National Institute on Drug Abuse in the 
United States has recently warned that COVID-19 could be a serious danger for populations with 
substance use disorders, including people who smoke or vape tobacco or cannabis (National Institute 
on Drug Abuse, 2020). Rates of cannabis use among adults aged 65 years and older has been rising 
in Canada. Older adults are at greater risk of developing respiratory and cardiovascular complications, 
and the co-occurrence of cannabis smoking and COVID-19 could increase the risk of these 
complications. Impaired lung function could put people who smoke or vape cannabis at risk for 
serious complications from COVID-19. The extent to which cannabis smoke impacts respiratory and 
immune health in humans is currently not well-known. However, in light of the ongoing COVID-19 
pandemic, any behaviours that might put an individual’s health at risk should be carefully considered; 
this includes smoking and vaping cannabis.  
More information about cannabis and its effects on the lungs and heart is coming soon in CCSA’s 
Clearing the Smoke on Cannabis Series. 
Complementary Resources  
Health Services and Mental Health Support Resources  
• ConnexOntario, Addiction, Mental Health, and Problem Gambling Treatment Service: 
https://www.connexontario.ca/  
• Ontario Telemedicine Network, Clinical Resources to Support COVID-19 and the Use of Virtual 
Care: https://otn.ca/covid-19/ 
• Telehealth Ontario, Get Medical Advice: https://www.ontario.ca/page/get-medical-advice-
telehealth-ontario?_ga=1.82142430.912117515.1445957549 
• CannabisRehab.org, Online Rehab Group: https://www.cannabisrehab.org/ 
Cannabis Resources 
• Canadian Institute for Substance Use Research, Safer Cannabis Use: 
https://www.heretohelp.bc.ca/infosheet/safer-cannabis-use-marijuana-hash-hash-oil 
• Centre for Addiction and Mental Health, Canada’s Lower-Risk Cannabis Use Guidelines: 
https://www.camh.ca/-/media/files/pdfs---reports-and-books---research/canadas-lower-risk-
guidelines-cannabis-pdf.pdf 
• Government of Canada, Cannabis in Canada: Get the facts: 
https://www.canada.ca/en/services/health/campaigns/cannabis.html 
COVID-19 Resources 
• Government of Canada, Coronavirus disease (COVIC-19): https://www.canada.ca/en/public-
health/services/diseases/coronavirus-disease-covid-19.html 
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• Substance Abuse and Mental Health Services Administration, Considerations for the Care and 
Treatment of Mental and Substance Use Disorders in the COVID-19 Epidemic: 
https://www.samhsa.gov/sites/default/files/considerations-care-treatment-mental-substance-
use-disorders-covid19.pdf   
• National Institute on Drug Abuse, COVID-19: Potential Implications for Individuals with Substance 
Use Disorders: https://www.drugabuse.gov/about-nida/noras-blog/2020/03/covid-19-potential-
implications-individuals-substance-use-disorders   
• World Health Organization, Rolling updates on coronavirus disease (COVID-19): 
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen  
• Centers for Disease Control and Prevention, Coronavirus (COVID-19): 
https://www.cdc.gov/coronavirus/2019-ncov/index.html  
• National Institutes of Health, Coronavirus disease 2019: https://www.nih.gov/health-
information/coronavirus#!/detail/403327  
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CCSA was created by Parliament to provide national leadership to address substance use in 
Canada. A trusted counsel, we provide national guidance to decision makers by harnessing 
the power of research, curating knowledge and bringing together diverse perspectives. 
CCSA activities and products are made possible through a financial contribution from 
Health Canada. The views of CCSA do not necessarily represent the views of Health 
Canada. 
